Half of NCI Cancer Center Physician Directors Received Industry Payments in 2017

Article

In 2017, about half of physician directors at National Cancer Institute cancer centers received payments related to research, while a quarter received payments over $5,000 that were not related to research.

In 2017, about half of physician directors of National Cancer Institute (NCI) cancer centers received industry payments, according to a new research letter published in JAMA Internal Medicine.

“Our findings raise the question of whether industry payments to the directors of publicly supported institutions, such as NCI-designated cancer centers, serve the public interest,” David Carr, MD, of University of California, San Diego, and H. Gilbert Welch, MD, MPH, of Thetford, Vermont, wrote in the research letter in JAMA Internal Medicine. “Policy makers-and the public-should consider whether such payments should be allowed, limited, or eliminated.”

Carr and Welch used data from 2015 to 2017 in the Open Payments database, which includes payments from pharmaceutical and medical device companies for all US physicians. In 2017, there were 53 physician directors of NCI-designated cancer centers. Of these, 44 held the same position in 2016 and 41 in 2015.

Payments totaled $4.42 million in 2017, including $1.89 million in research payments to 12 directors, and $2.53 million in non-research payments to 22 directors. Only about one-half of physician directors of National Cancer Institute (NCI) cancer centers received industry payments in 2017, while one-quarter received a payment of “significant financial interest” unrelated to research.

The NCI defines payments over $5,000 that are unrelated to research as being a “significant financial interest.” Twenty-three percent of payments unrelated to research in 2017 exceeded $5,000.

Twenty-seven of the 53 directors (51%) received no payments, but 19 (36%) received payments over $5,000 that were unrelated to research. Two directors received non-research payments of more than $50,000. One of these two large payments was for $2.27 million, almost all of which was categorized in Open Payment as being for “compensation for services other than consulting, including serving as faculty or a speaker at a venue other than a continuing education program.”

The researchers noted that “the NCI conflict of interest policy is silent on research payments”. The largest research payment in 2017 was $863,000. Of 12 physician directors who received research payments, 10 were for more than $5,000 and four for more than $50,000.

Carr and Welch noted that information in the database is limited because it lacks data about services provided and provides no information on whether payment influence the physician directors.  

Recent Videos
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
2 experts are featured in this series.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Related Content